News | December 06, 2023
Sun Pharmaceutical inks licensing agreement with Aclaris Therapeutics
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Decision on EU marketing authorisation expected for momelotinib by early 2024
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
